Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Benign acute viral myositis in African migrants: A clinical, serological, and pathological study.

Pancheri E, Lanzafame M, Zamò A, Angheben A, Sartoris S, Zorzi A, Boaretti M, Signoretto C, Guglielmi V, Ferrari S, Tonin P, Vattemi G.

Muscle Nerve. 2019 Nov;60(5):586-590. doi: 10.1002/mus.26679. Epub 2019 Aug 30.

PMID:
31443116
2.

Low plasmatic concentration of intensified antiretroviral therapy in a pregnant woman: a case report.

Chiesi S, Rizzardo S, Piacentini D, Be G, Lattuada E, Tacconelli E, Lanzafame M.

J Med Case Rep. 2019 Jul 23;13(1):224. doi: 10.1186/s13256-019-2148-y.

3.

Dolutegravir monotherapy and body weight gain in antiretroviral naïve patients.

Rizzardo S, Lanzafame M, Lattuada E, Luise D, Vincenzi M, Tacconelli E, Vento S.

AIDS. 2019 Aug 1;33(10):1673-1674. doi: 10.1097/QAD.0000000000002245. No abstract available.

PMID:
31305333
4.

Patient-centered Care and Treatment in HIV Infection.

Lanzafame M, Vento S.

EClinicalMedicine. 2019 Jan 10;6:5-6. doi: 10.1016/j.eclinm.2019.01.001. eCollection 2018 Dec. No abstract available.

5.

Relationship Between Vertebral Fractures, Bone Mineral Density, and Osteometabolic Profile in HIV and Hepatitis B and C-Infected Patients Treated With ART.

Dalla Grana E, Rigo F, Lanzafame M, Lattuada E, Suardi S, Mottes M, Valenti MT, Dalle Carbonare L.

Front Endocrinol (Lausanne). 2019 May 14;10:302. doi: 10.3389/fendo.2019.00302. eCollection 2019.

6.

Efavirenz dose reduction is associated with improved lipid profile in HIV-1 infected patients.

Nicolè S, Lanzafame M, Lattuada E, Luise D, Vecchi M, Tacconelli E, Vento S.

Infect Dis (Lond). 2019 Aug;51(8):615-617. doi: 10.1080/23744235.2019.1609078. Epub 2019 May 12. No abstract available.

PMID:
31081419
7.

Novel biomarkers for primary biliary cholangitis to improve diagnosis and understand underlying regulatory mechanisms.

Bombaci M, Pesce E, Torri A, Carpi D, Crosti M, Lanzafame M, Cordiglieri C, Sinisi A, Moro M, Bernuzzi F, Gerussi A, Geginat J, Muratori L, Terracciano LM, Invernizzi P, Abrignani S, Grifantini R.

Liver Int. 2019 Nov;39(11):2124-2135. doi: 10.1111/liv.14128. Epub 2019 May 15.

PMID:
31033124
8.

Efficacy and safety of abacavir/lamivudine with raltegravir in treatment-experienced and treatment-naïve patients with HIV-1 infection: an observational, retrospective, multi-centre study.

Rizzardo S, Lanzafame M, Lattuada E, Bragantini D, Nicolè S, Calza L, Tacconelli E.

Int J STD AIDS. 2019 Apr;30(5):467-471. doi: 10.1177/0956462418817049. Epub 2019 Jan 10.

PMID:
30999834
9.

DRIVE-AHEAD Trial's Results and the Need for a More Appropriate Comparator Drug.

Lanzafame M, Lattuada E, Vento S.

Clin Infect Dis. 2019 Oct 30;69(10):1832. doi: 10.1093/cid/ciz227. No abstract available.

PMID:
30891602
10.

Dolutegravir Monotherapy's Virological Efficacy in a Highly Treatment-Experienced Patient.

Lanzafame M, Lattuada E, Rizzardo S, Piacentini D, Chiesi S, Mazzi R.

AIDS Res Hum Retroviruses. 2019 Apr;35(4):359-360. doi: 10.1089/AID.2018.0117. Epub 2019 Jan 22. No abstract available.

PMID:
30525872
11.

Dolutegravir monotherapy: an option for highly adherent HIV1-infected naive patients with relatively low zenith HIV-RNA?

Lanzafame M, Rizzardo S, Piacentini D, Lattuada E, Chiesi S, Vento S.

Infect Dis (Lond). 2019 Jan;51(1):77-78. doi: 10.1080/23744235.2018.1518585. Epub 2018 Oct 14. No abstract available.

PMID:
30317907
12.

Immunovirological outcome and HIV-1 DNA decay in a small cohort of HIV-1-infected patients deintensificated from Abacavir/Lamivudine/Dolutegravir to Lamivudine plus Dolutegravir.

Lanzafame M, Nicole S, Rizzardo S, Piacentini D, Chiesi S, Lattuada E, Diani E, Carelli M, Vento S, Gibellini D.

New Microbiol. 2018 Oct;41(4):262-267. Epub 2018 Oct 12.

13.

Mycobacterium chimaera infections following cardiac surgery in Italy: results from a National Survey Endorsed by the Italian Society of Cardiac Surgery.

Cappabianca G, Paparella D, D'Onofrio A, Caprili L, Minniti G, Lanzafame M, Parolari A, Musumeci F, Beghi C.

J Cardiovasc Med (Hagerstown). 2018 Dec;19(12):748-755. doi: 10.2459/JCM.0000000000000717.

PMID:
30300243
14.

HIV-1-Associated Neurocognitive Disorders: Is HLA-C Binding Stability to β2-Microglobulin a Missing Piece of the Pathogenetic Puzzle?

Zipeto D, Serena M, Mutascio S, Parolini F, Diani E, Guizzardi E, Muraro V, Lattuada E, Rizzardo S, Malena M, Lanzafame M, Malerba G, Romanelli MG, Tamburin S, Gibellini D.

Front Neurol. 2018 Sep 21;9:791. doi: 10.3389/fneur.2018.00791. eCollection 2018.

15.

Diagnostic Targeted Sequencing Panel for Hepatocellular Carcinoma Genomic Screening.

Paradiso V, Garofoli A, Tosti N, Lanzafame M, Perrina V, Quagliata L, Matter MS, Wieland S, Heim MH, Piscuoglio S, Ng CKY, Terracciano LM.

J Mol Diagn. 2018 Nov;20(6):836-848. doi: 10.1016/j.jmoldx.2018.07.003. Epub 2018 Aug 22.

PMID:
30142445
16.

"High" antiretroviral deintensification, a strategy to avoid drug interactions and unfavourable long-term effects of HAART.

Lanzafame M, Piacentini D, Lattuada E, Rizzardo S, Chiesi S, Vento S.

Infect Dis (Lond). 2018 Oct;50(10):788-790. doi: 10.1080/23744235.2018.1482420. Epub 2018 Jun 19. No abstract available.

PMID:
29916752
17.

Darunavir/ritonavir 600/100 mg once daily: it's time for larger non-inferiority randomized trials.

Nicolè S, Lanzafame M, Cucchetto G, Rigo F, Lattuada E, Concia E.

J Antimicrob Chemother. 2018 Jun 1;73(6):1728-1730. doi: 10.1093/jac/dky086. No abstract available.

PMID:
29608687
18.

Functional and clinical relevance of novel mutations in a large cohort of patients with Cockayne syndrome.

Calmels N, Botta E, Jia N, Fawcett H, Nardo T, Nakazawa Y, Lanzafame M, Moriwaki S, Sugita K, Kubota M, Obringer C, Spitz MA, Stefanini M, Laugel V, Orioli D, Ogi T, Lehmann AR.

J Med Genet. 2018 May;55(5):329-343. doi: 10.1136/jmedgenet-2017-104877. Epub 2018 Mar 23.

PMID:
29572252
19.

The treatment of latent TB infection in HIV-positive people: the Verona experience.

Cordioli M, Mazzaferri F, Fasani G, Del Bravo P, Lattuada E, Vento S, Concia E, Lanzafame M.

Infez Med. 2018 Mar 1;26(1):107-109.

20.

Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study.

Ng CKY, Di Costanzo GG, Tosti N, Paradiso V, Coto-Llerena M, Roscigno G, Perrina V, Quintavalle C, Boldanova T, Wieland S, Marino-Marsilia G, Lanzafame M, Quagliata L, Condorelli G, Matter MS, Tortora R, Heim MH, Terracciano LM, Piscuoglio S.

Ann Oncol. 2018 May 1;29(5):1286-1291. doi: 10.1093/annonc/mdy083.

PMID:
29509837
21.

The Role of Long Non-Coding RNAs in Hepatocarcinogenesis.

Lanzafame M, Bianco G, Terracciano LM, Ng CKY, Piscuoglio S.

Int J Mol Sci. 2018 Feb 28;19(3). pii: E682. doi: 10.3390/ijms19030682. Review.

22.

Genomic Analysis Revealed New Oncogenic Signatures in TP53-Mutant Hepatocellular Carcinoma.

Kancherla V, Abdullazade S, Matter MS, Lanzafame M, Quagliata L, Roma G, Hoshida Y, Terracciano LM, Ng CKY, Piscuoglio S.

Front Genet. 2018 Feb 2;9:2. doi: 10.3389/fgene.2018.00002. eCollection 2018.

23.

Dolutegravir monotherapy in HIV-1-suppressed patients: A feasible regimen in real life.

Lattuada E, Lanzafame M, Nicolè S, Rigo F, Cucchetto G, Concia E, Vento S.

Int J STD AIDS. 2018 Feb;29(2):206-207. doi: 10.1177/0956462417747832. No abstract available.

PMID:
29320967
24.

Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy.

Calza L, Cafaggi M, Colangeli V, Borderi M, Barchi E, Lanzafame M, Nicole' S, Degli Antoni AM, Bon I, Re MC, Viale P.

Infect Dis (Lond). 2018 May;50(5):352-360. doi: 10.1080/23744235.2017.1410285. Epub 2017 Dec 6.

PMID:
29210336
25.

High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models.

Quagliata L, Quintavalle C, Lanzafame M, Matter MS, Novello C, di Tommaso L, Pressiani T, Rimassa L, Tornillo L, Roncalli M, Cillo C, Pallante P, Piscuoglio S, Ng CK, Terracciano LM.

Lab Invest. 2018 Jan;98(1):95-105. doi: 10.1038/labinvest.2017.107. Epub 2017 Oct 16.

26.

Disseminated Mycobacterium chimaera infection after open heart surgery in an Italian woman: a case report and a review of the literature.

Chiesi S, Piacentini D, Salerno ND, Luise D, Peracchi M, Concia E, Cazzadori A, Piovan E, Lanzafame M.

Infez Med. 2017 Sep 1;25(3):267-269. Review.

27.

Successful Antifungal Combination Therapy and Surgical Approach for Aspergillus fumigatus Suppurative Thyroiditis Associated with Thyrotoxicosis and Review of Published Reports.

Nicolè S, Lanzafame M, Cazzadori A, Vincenzi M, Mangani F, Colato C, El Dalati G, Brazzarola P, Concia E.

Mycopathologia. 2017 Oct;182(9-10):839-845. doi: 10.1007/s11046-017-0145-5. Epub 2017 May 29. Review.

PMID:
28555254
28.

Dual therapy with a combination of unboosted atazanavir and lamivudine as maintenance treatment in virologically suppressed HIV-1-infected patients.

Rigo F, Cucchetto G, Lanzafame M, Nicolè S, Lattuada E, Concia E, Vento S.

HIV Med. 2017 Nov;18(10):790-792. doi: 10.1111/hiv.12523. Epub 2017 May 15. No abstract available.

29.

Raltegravir plus lamivudine as 'maintenance therapy' in suppressed HIV-1-infected patients in real-life settings.

Cucchetto G, Lanzafame M, Nicolè S, Lattuada E, Calza L, Concia E.

J Antimicrob Chemother. 2017 Jul 1;72(7):2138-2140. doi: 10.1093/jac/dkx106. No abstract available.

PMID:
28419270
30.

The burden and epidemiology of community-acquired central nervous system infections: a multinational study.

Erdem H, Inan A, Guven E, Hargreaves S, Larsen L, Shehata G, Pernicova E, Khan E, Bastakova L, Namani S, Harxhi A, Roganovic T, Lakatos B, Uysal S, Sipahi OR, Crisan A, Miftode E, Stebel R, Jegorovic B, Fehér Z, Jekkel C, Pandak N, Moravveji A, Yilmaz H, Khalifa A, Musabak U, Yilmaz S, Jouhar A, Oztoprak N, Argemi X, Baldeyrou M, Bellaud G, Moroti RV, Hasbun R, Salazar L, Tekin R, Canestri A, Čalkić L, Praticò L, Yilmaz-Karadag F, Santos L, Pinto A, Kaptan F, Bossi P, Aron J, Duissenova A, Shopayeva G, Utaganov B, Grgic S, Ersoz G, Wu AKL, Lung KC, Bruzsa A, Radic LB, Kahraman H, Momen-Heravi M, Kulzhanova S, Rigo F, Konkayeva M, Smagulova Z, Tang T, Chan P, Ahmetagic S, Porobic-Jahic H, Moradi F, Kaya S, Cag Y, Bohr A, Artuk C, Celik I, Amsilli M, Gul HC, Cascio A, Lanzafame M, Nassar M.

Eur J Clin Microbiol Infect Dis. 2017 Sep;36(9):1595-1611. doi: 10.1007/s10096-017-2973-0. Epub 2017 Apr 10.

PMID:
28397100
31.

Dolutegravir monotherapy in HIV-infected naive patients with an HIV-RNA load <100 000 copies/mL: a medium-term follow-up.

Lanzafame M, Nicolè S, Gibellini D, Lattuada E, Cucchetto G, Rigo F, Diani E, Concia E, Vento S.

J Antimicrob Chemother. 2017 Jul 1;72(7):2136-2138. doi: 10.1093/jac/dkx109. No abstract available.

PMID:
28387810
32.

Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient.

Lanzafame M, Lattuada E, Nicolè S, Rigo F, Cucchetto G, Concia E, Vento S.

Int J STD AIDS. 2017 Jun;28(7):726-728. doi: 10.1177/0956462416678164. Epub 2016 Oct 27.

PMID:
27789848
33.

Overexpression of parkin rescues the defective mitochondrial phenotype and the increased apoptosis of Cockayne Syndrome A cells.

Pascucci B, D'Errico M, Romagnoli A, De Nuccio C, Savino M, Pietraforte D, Lanzafame M, Calcagnile AS, Fortini P, Baccarini S, Orioli D, Degan P, Visentin S, Stefanini M, Isidoro C, Fimia GM, Dogliotti E.

Oncotarget. 2016 Jun 7;8(61):102852-102867. doi: 10.18632/oncotarget.9913. eCollection 2017 Nov 28.

34.

Dolutegravir Monotherapy in HIV-Infected Naive Patients With <100,000 Copies/mL HIV RNA Load.

Lanzafame M, Gibellini D, Lattuada E, Signoretto C, Mazzi R, Concia E, Vento S.

J Acquir Immune Defic Syndr. 2016 May 1;72(1):e12-4. doi: 10.1097/QAI.0000000000000931. No abstract available.

PMID:
27097366
35.

GTF2E2 Mutations Destabilize the General Transcription Factor Complex TFIIE in Individuals with DNA Repair-Proficient Trichothiodystrophy.

Kuschal C, Botta E, Orioli D, Digiovanna JJ, Seneca S, Keymolen K, Tamura D, Heller E, Khan SG, Caligiuri G, Lanzafame M, Nardo T, Ricotti R, Peverali FA, Stephens R, Zhao Y, Lehmann AR, Baranello L, Levens D, Kraemer KH, Stefanini M.

Am J Hum Genet. 2016 Apr 7;98(4):627-42. doi: 10.1016/j.ajhg.2016.02.008. Epub 2016 Mar 17.

36.

Tuberculosis-immune reconstitution inflammatory syndrome.

Lanzafame M, Vento S.

J Clin Tuberc Other Mycobact Dis. 2016 Mar 11;3:6-9. doi: 10.1016/j.jctube.2016.03.002. eCollection 2016 May. Review.

PMID:
31723680
37.

Monoclonal Gammopathy in HIV-Infected Patients on Stable Antiretroviral Therapy: Disappearance or Deep Reduction?

Mazzaferri F, Cordioli M, Lattuada E, Veneri D, Concia E, Lanzafame M.

J Acquir Immune Defic Syndr. 2016 May 1;72(1):e11-2. doi: 10.1097/QAI.0000000000000925. No abstract available.

PMID:
26689973
38.

Raltegravir Plus Nevirapine as Maintenance Antiretroviral Therapy in HIV-Positive Patients: Safety, Efficacy and Pharmacokinetics.

Calcagno A, Montrucchio C, Capetti A, Guaraldi G, Cenderello G, Calza L, Lanzafame M, Marinaro L, Tettoni MC, Trentini L, D'Avolio A, Di Perri G, Bonora S.

Curr HIV Res. 2016;14(1):54-60.

PMID:
26415700
39.

Raltegravir/nevirapine dual therapy at reduced doses as 'maintenance' treatment in virally suppressed HIV-infected patients.

Lanzafame M, Lattuada E, Rigo F, Nicole S, Cucchetto G, Vento S.

AIDS. 2015 Aug 24;29(13):1722-3. doi: 10.1097/QAD.0000000000000775. No abstract available.

PMID:
26372286
40.

Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study).

Bonora S, Rusconi S, Calcagno A, Bracchi M, Viganò O, Cusato J, Lanzafame M, Trentalange A, Marinaro L, Siccardi M, D'Avolio A, Galli M, Di Perri G.

J Antimicrob Chemother. 2015 Nov;70(11):3096-9. doi: 10.1093/jac/dkv208. Epub 2015 Jul 14.

41.

Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study.

Matinella A, Lanzafame M, Bonometti MA, Gajofatto A, Concia E, Vento S, Monaco S, Ferrari S.

J Neurol. 2015 May;262(5):1317-27. doi: 10.1007/s00415-015-7713-8. Epub 2015 Apr 1.

PMID:
25877836
42.

Performance of Alere Determine HIV-1/2 Ag/Ab Combo rapid test for acute HIV infection: a case report.

Lanzafame M, Zorzi A, Rigo F, Adami I, Del Bravo P, Tonolli E, Concia E, Azzini AM.

Infez Med. 2015 Mar;23(1):48-50.

43.

Reference genes for gene expression analysis in proliferating and differentiating human keratinocytes.

Lanzafame M, Botta E, Teson M, Fortugno P, Zambruno G, Stefanini M, Orioli D.

Exp Dermatol. 2015 Apr;24(4):314-6. doi: 10.1111/exd.12657.

PMID:
25651864
44.

TFIIH-dependent MMP-1 overexpression in trichothiodystrophy leads to extracellular matrix alterations in patient skin.

Arseni L, Lanzafame M, Compe E, Fortugno P, Afonso-Barroso A, Peverali FA, Lehmann AR, Zambruno G, Egly JM, Stefanini M, Orioli D.

Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1499-504. doi: 10.1073/pnas.1416181112. Epub 2015 Jan 20.

45.

Virological efficacy of a reduced dose of nevirapine in a small cohort of suppressed HIV-1-infected patients.

Lanzafame M, Lattuada E, Cucchetto G, Nicolè S, Concia E, Vento S.

J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):e59-61. doi: 10.1097/QAI.0000000000000505. No abstract available.

PMID:
25559599
46.

Efavirenz dose reduction in HIV-infected patients: a long-term follow-up.

Lanzafame M, Lattuada E, Cucchetto G, Concia E, Vento S.

AIDS. 2014 Nov 28;28(18):2789-90. doi: 10.1097/QAD.0000000000000482. No abstract available.

PMID:
25493605
47.

Efficacy of a reduced dose of DARUNAVIR/RTV in a cohort of antiretroviral-naïve and experienced HIV-infected patients: a medium-term follow-up.

Lanzafame M, Lattuada E, Rigo F, Hill A, Vento S.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19822. doi: 10.7448/IAS.17.4.19822. eCollection 2014.

48.

Efficacy of a reduced dose of darunavir/ritonavir in a cohort of antiretroviral-naive and -experienced HIV-infected patients: a medium-term follow-up.

Lanzafame M, Lattuada E, Rigo F, Ferrari A, Hill A, Vento S.

J Antimicrob Chemother. 2015 Feb;70(2):627-30. doi: 10.1093/jac/dku390. Epub 2014 Oct 8. No abstract available.

PMID:
25298517
49.

Disappearance of renal stones in an HIV-1-infected patient after reduction of atazanavir dose.

Lanzafame M, Bonora S, Lattuada E, Calcagno A, Di Perri G, Concia E.

AIDS Res Hum Retroviruses. 2014 Sep;30(9):835-6. doi: 10.1089/AID.2014.0134. Epub 2014 Jul 31. No abstract available.

50.

[Budget impact analysis of efavirenz daily dose reduction at the Verona University Hospital].

Costa E, Biasi V, Concia E, Jommi C, Lattuada E, Manfre S, Venturini F, Lanzafame M.

Infez Med. 2014 Jun;22(2):118-23. Italian.

Supplemental Content

Loading ...
Support Center